Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | NMT1 | P30419 | 4/20 | 0.39 |
| ▸ | NMT2 | O60551 | 3/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133400 | 0.86 | FOLH1 (0.44) | QRFPRFOLH1HPGDSNOD1 | |
| SCHEMBL15295145 | 0.82 | FOLH1 (0.49) | TLR2FOLH1ROCK2NMT1NMT2 | |
| SCHEMBL14300277 | 0.80 | FOLH1 (0.44) | FOLH1HPGDSNOD1 | |
| SCHEMBL1227505 | 0.79 | TLR2 (0.49) | TLR2FOLH1ROCK2NMT1NMT2 | |
| SCHEMBL17087779 | 0.78 | QRFPR (0.34) | QRFPRTLR2FOLH1ROCK2HRH1 | |
| SCHEMBL16330790 | 0.78 | SIRT5 (0.50) | TLR2FOLH1ROCK2SIRT5 | |
| SCHEMBL26440808 | 0.78 | FOLH1 (0.42) | QRFPRFOLH1 | |
| SCHEMBL24618910 | 0.77 | CHRM5 (0.44) | FOLH1 | |
| SCHEMBL22574289 | 0.77 | CHRM5 (0.44) | FOLH1 | |
| SCHEMBL22488337 | 0.77 | FOLH1 (0.62) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200108159-A1 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | WAKE FOREST UNIVERSITY | 2020-04-09 | — | — | US | disclosed |
| US-20180126013-A1 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | WAKE FOREST UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180126013-A1 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | MC1R, MC3R, MC5R | QRFPR 137/4885TLR2 1575/4885FOLH1 82/4885 |
| US-20200108159-A1 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | MC1R, MC3R, MC5R | QRFPR 137/4885TLR2 1575/4885FOLH1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.